Avidity biosciences appoints steve hughes, m.d., as chief medical officer

San diego, feb. 23, 2022 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced the appointment of steve hughes, m.d. as chief medical officer.

RNA Ratings Summary

RNA Quant Ranking